[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025",
    "summary": "PRINCETON, N.J., December 08, 2025--Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025",
    "url": "https://finnhub.io/api/news?id=624fc2ca94f001efd0a7988fd9dc2a0958387114ec160219f305afd6d12a4523",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765229400,
      "headline": "Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025",
      "id": 137737983,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., December 08, 2025--Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025",
      "url": "https://finnhub.io/api/news?id=624fc2ca94f001efd0a7988fd9dc2a0958387114ec160219f305afd6d12a4523"
    }
  },
  {
    "ts": null,
    "headline": "Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?",
    "summary": "Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.",
    "url": "https://finnhub.io/api/news?id=8ccde1e9188043d29f9e3b16a5a60ba25325e9ddddba86ad5887d50b1d28f2e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765219980,
      "headline": "Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?",
      "id": 137737710,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.",
      "url": "https://finnhub.io/api/news?id=8ccde1e9188043d29f9e3b16a5a60ba25325e9ddddba86ad5887d50b1d28f2e3"
    }
  },
  {
    "ts": null,
    "headline": "Leerink Maintains Outperform Rating as Bristol Myers (BMY) Expands ADEPT-2 Enrollment",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, Leerink analyst David Risinger maintained an Outperform rating on Bristol-Myers Squibb Company (NYSE:BMY). The analyst highlighted that the company plans to enroll more patients in the ADEPT-2 study and sees this as a positive development. […]",
    "url": "https://finnhub.io/api/news?id=69a14969fc84c6747a47f6de993b7f5897b2209415288c8a08d951df043786f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765213476,
      "headline": "Leerink Maintains Outperform Rating as Bristol Myers (BMY) Expands ADEPT-2 Enrollment",
      "id": 137737985,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, Leerink analyst David Risinger maintained an Outperform rating on Bristol-Myers Squibb Company (NYSE:BMY). The analyst highlighted that the company plans to enroll more patients in the ADEPT-2 study and sees this as a positive development. […]",
      "url": "https://finnhub.io/api/news?id=69a14969fc84c6747a47f6de993b7f5897b2209415288c8a08d951df043786f9"
    }
  }
]